We invite you to meet with our colleague Dr. William Kelce, OncoBay’s strategic regulatory expert.  William specializes in working hand-in-hand with emerging drug development companies to manage the often-difficult transition from promising academic research to focused drug development, including defining the most efficient regulatory pathway and designing regulatory-compliant, nonclinical development programs intended to maximize product labeling and minimize development costs and timelines. Contributing to hundreds of regulatory submissions with primary authorship for 50+ INDs, NDAS and BLAs, William’s successful experiences over the past 30 years are significant.

If you have any questions about your current regulatory strategy or are interested in finding out how we can help you transition from benchtop to clinic including support through a successful IND filing, we invite you book some time with Dr. Kelce during the meeting. The following link will allow you to schedule time as it’s convenient. Alternatively please feel free to reach out to me and I’m happy to coordinate sometime at your mutual convenience.


Share This

Exom is now Kapadi


Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.

Visit Kapadi.com